TraumaPhase 2KetNCT03233035
Low Dose Ketamine Intra Nasal Traumatology
A Phase 2 study testing Ketamine in people with Trauma, run by University of Monastir at 2 sites in Tunisia.
Trial summary
To evaluate the efficacy and safety of early administration of low-dose intranasal ketamine analgesic agents in patients with moderate to severe pain in the ED in reducing the need for opioid or non opioids analgesic agents. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Trauma
- What is being tested?
- Ketamine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 1,102 participants
- Where
- 2 sitesTunisia
- Study dates
- 1 Jan 2018to 1 Dec 2018
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- The study includes patients aged 18 to 80 years who presented to the ED with acute limb trauma pain with a visual analgesic scale (VAS) of 5 or more on a standard 11- point (0 to 10). An informed consent is necessary.
Who cannot join
- - Pregnancy,
- Breast-feeding,
- Altered mental status,
- Allergy to ketamine or morphine or
- Weight less than 46 kg or greater than 115 kg,
- Unstable vital signs (systolic blood pressure <90 or >180 mm Hg, pulse rate <50 or >150 beats/min, and respiration rate <10 or >30 breaths/min),
Show all 10Show fewer
- Medical history of acute head or eye injury, seizure, intracranial hypertension, chronic pain, severre renal or hepatic insufficiency,
- Alcohol or drug abuse,
- Psychiatric illness,
- Recent (4 hours before) analgesic agent use.
Trial locations and contacts
2 sites in 1 country.
Tunisia2 sites
Nouira Samir
Monastir, Emergency Department Monastir, Tunisia 5000, 5000
Emergency department of university hospital Fattouma Bourguiba of Monastir
Monastir, 5000
About this study
Official title: Intranasal Ketamine for Treatment of Acute Pain in the Emergency Department : A Randomized Controlled Trial
To evaluate the efficacy and safety of early administration of low-dose intranasal ketamine analgesic agents in patients with moderate to severe pain in the ED in reducing the need for opioid or non opioids analgesic agents.
Read the detailed description
Intranasal ketamine for treatment of acute pain in the emergency department : A randomized controlled trial
Introduction :
Pain is the most common complaint for emergency department (ED) visits [1].The provision of adequate, safe, and timely analgesia is a core component of patient care in the emergency department (ED). Ketamine is a noncompetitive Nmethyl- D-aspartate and glutamate receptor antagonist that decreases central sensitization, "wind-up" phenomena, and pain memory [2,3].
At subdissociative doses (0.1 to 0.6 mg/kg; most commonly 0.3 mg/kg) maintains potent analgesic and amnestic effects that are accompanied by preservation of protective airway reflexes, spontaneous respiration, and cardiopulmonary stability [4-6].
Intranasal route ….
Objective of the study :
To evaluate the efficacy and safety of early administration of low-dose intranasal ketamine analgesic agents in patients with moderate to severe pain in the ED in reducing the need for opioid or class III analgesic agents.
Materials and Methods :
Study design :
It is a ramdomized, prospective, double blind, controlled, multicentric trial. The study is registered with clinical.tria.gov (…….).
Study Setting and Selection of Participants :
The trial is conducted in three community teaching hospitals :
- Emergency department, fattouma bourguiba university hospital, monastir, tunisia
- Emergency department, sahloul university hospital, sousse, tunisia
- Emergency department, farhat hached university hospital, sousse, tunisia
ED principal investigators maintain the randomization list, which is generated before the start of the study, prepare the medication, and deliver it to the treating physician in a blinded manner.
Inclusion criteria :
The study includes patients aged 18 to 80 years who presented to the ED with acute limb trauma pain with a visual analogue scale (VAS) of 5 or more on a standard 11- point (0 to 10). An informed consent is necessary.
Exclusion criteria :
- Pregnancy,
- Breast-feeding,
- Altered mental status,
- Allergy to ketamine or morphine or
- Weight less than 46 kg or greater than 115 kg,
- Unstable vital signs (systolic blood pressure <90 or >180 mm Hg, pulse rate <50 or >150 beats/min, and respiration rate <10 or >30 breaths/min),
- Medical history of acute head or eye injury, seizure, intracranial hypertension, chronic pain, severre renal or hepatic insufficiency,
- Alcohol or drug abuse,
- Psychiatric illness,
- Recent (4 hours before) analgesic agent use.
Protocol :
In the triage area, each patient having the inclusion criteria receives 25mg of ketamine in 0.5 ml of serum saline in one pulverisation per nostril or 0.5 mL of normal saline solution in one pulverisation per nostril as a placebo according to the predetermined randomization list. None of the treating physician or nurses is aware about the medication received. In all patients included, the investigators collect vital signs ; demographic and clinical data.
Study investigators record VAS, and adverse effects at 15, 30, 60, 90, and 120 minutes.
At 30 minutes, if patients report a pain numeric rating scale score of 5 or greater and request additional pain relief, titrated morphine is administered as a rescue analgesic with a dose of 0.1 mg/Kg repeated every 3 to 5 minutes if the pain numeric rating scale score is still greater or equal to 3.
All data recorded on data collection sheets, including sex, demographics, medical history, and vital signs, were entered into SPSS (version 20.0; IBM Corp) by the research manager.
Patients's informed consent is obtained. The ethic commitee of our institution approved the study.
Endpoints :
Primary endpoints :
- Need for rescue opioids during ED stay
Secondary endpoints :
- requirement of non-opioids analgesic agents.
- percentage of patients discharged from the ED with VAS <30.
- Safety : adverse events
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
KetamineDrug
25mg of ketamine in 0.5 ml of serum saline in one pulverisation per nostril is received
PlaceboDrug
Also called normal saline solution
0.5 mL of normal saline solution as a placebo in one pulverisation per nostril
| Study group | Role | What they receive |
|---|---|---|
| placebo group | Placebo comparator | Intranasal placebo pulverisation Receives: Drug: Placebo |
| Ketamine group | Active comparator | Intranasal ketamine pulverisation Receives: Drug: Ketamine |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number and percentage of patients who need rescue opiods in the two groups
the need for rescue opioids during ED stay
Measured: 30 minutes
Secondary outcomes (3)
Intolerance to treatement and adverse events
Noticing any sign of intolerance due to treatement : Dizziness , Vomiting..
Measured: 30 minutes and at 120 minutes
Percentage of patients with VAS <30 mm at discharge
percentage of patients discharged from the ED with VAS <30.
Measured: 120 minutes
Number and percentage of patients who required non opiods analgesics
Requirement of non-opioids analgesic agents
Measured: 30 minutes
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Jul 2017
- Study start1 Jan 2018
- Primary completion1 Dec 2018
- Study completion1 Dec 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for TraumaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Double Blind Study
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 1,102 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Monastir
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Pr. Semir Nouira, University of Monastir
- Investigators
- Nouira Semir, Professor, Principal investigator, university Hospital of Monastir
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03233035
- Sponsor's protocol ID
- Ket-Int-Nas-TR
- Acronym
- Ket
- Status last verified
- Jun 2019
- First submitted
- 14 May 2017
- Last updated
- 2 Jul 2019
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Jul 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Intranasal Ketamine for Treatment of Acute Pain in the Emergency Department : A Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT03233035
- Acronym / sponsor ID
- Ket / Ket-Int-Nas-TR
- Conditions
- Trauma
- Keywords
- Ketamine-Intranasal-Acute pain-Emergency departement
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 1,102 participants (actual)
- Lead sponsor
- University of MonastirUniversity, hospital or other
- Study start
- 1 Jan 2018 (actual)
- Primary completion
- 1 Dec 2018 (actual)
- Study completion
- 1 Dec 2018 (actual)
- First posted
- 28 Jul 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To evaluate the efficacy and safety of early administration of low-dose intranasal ketamine analgesic agents in patients with moderate to severe pain in the ED in reducing the need for opioid or non opioids analgesic agents.
Detailed description
Intranasal ketamine for treatment of acute pain in the emergency department : A randomized controlled trial
Introduction :
Pain is the most common complaint for emergency department (ED) visits [1].The provision of adequate, safe, and timely analgesia is a core component of patient care in the emergency department (ED). Ketamine is a noncompetitive Nmethyl- D-aspartate and glutamate receptor antagonist that decreases central sensitization, "wind-up" phenomena, and pain memory [2,3].
At subdissociative doses (0.1 to 0.6 mg/kg; most commonly 0.3 mg/kg) maintains potent analgesic and amnestic effects that are accompanied by preservation of protective airway reflexes, spontaneous respiration, and cardiopulmonary stability [4-6].
Intranasal route ….
Objective of the study :
To evaluate the efficacy and safety of early administration of low-dose intranasal ketamine analgesic agents in patients with moderate to severe pain in the ED in reducing the need for opioid or class III analgesic agents.
Materials and Methods :
Study design :
It is a ramdomized, prospective, double blind, controlled, multicentric trial. The study is registered with clinical.tria.gov (…….).
Study Setting and Selection of Participants :
The trial is conducted in three community teaching hospitals :
- Emergency department, fattouma bourguiba university hospital, monastir, tunisia
- Emergency department, sahloul university hospital, sousse, tunisia
- Emergency department, farhat hached university hospital, sousse, tunisia
ED principal investigators maintain the randomization list, which is generated before the start of the study, prepare the medication, and deliver it to the treating physician in a blinded manner.
Inclusion criteria :
The study includes patients aged 18 to 80 years who presented to the ED with acute limb trauma pain with a visual analogue scale (VAS) of 5 or more on a standard 11- point (0 to 10). An informed consent is necessary.
Exclusion criteria :
- Pregnancy,
- Breast-feeding,
- Altered mental status,
- Allergy to ketamine or morphine or
- Weight less than 46 kg or greater than 115 kg,
- Unstable vital signs (systolic blood pressure <90 or >180 mm Hg, pulse rate <50 or >150 beats/min, and respiration rate <10 or >30 breaths/min),
- Medical history of acute head or eye injury, seizure, intracranial hypertension, chronic pain, severre renal or hepatic insufficiency,
- Alcohol or drug abuse,
- Psychiatric illness,
- Recent (4 hours before) analgesic agent use.
Protocol :
In the triage area, each patient having the inclusion criteria receives 25mg of ketamine in 0.5 ml of serum saline in one pulverisation per nostril or 0.5 mL of normal saline solution in one pulverisation per nostril as a placebo according to the predetermined randomization list. None of the treating physician or nurses is aware about the medication received. In all patients included, the investigators collect vital signs ; demographic and clinical data.
Study investigators record VAS, and adverse effects at 15, 30, 60, 90, and 120 minutes.
At 30 minutes, if patients report a pain numeric rating scale score of 5 or greater and request additional pain relief, titrated morphine is administered as a rescue analgesic with a dose of 0.1 mg/Kg repeated every 3 to 5 minutes if the pain numeric rating scale score is still greater or equal to 3.
All data recorded on data collection sheets, including sex, demographics, medical history, and vital signs, were entered into SPSS (version 20.0; IBM Corp) by the research manager.
Patients's informed consent is obtained. The ethic commitee of our institution approved the study.
Endpoints :
Primary endpoints :
- Need for rescue opioids during ED stay
Secondary endpoints :
- requirement of non-opioids analgesic agents.
- percentage of patients discharged from the ED with VAS <30.
- Safety : adverse events
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 2
- Model description
- Double Blind Study
| Arm | Type | Receives |
|---|---|---|
| placebo group | Placebo comparator | Drug: PlaceboIntranasal placebo pulverisation |
| Ketamine group | Active comparator | Drug: KetamineIntranasal ketamine pulverisation |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- The study includes patients aged 18 to 80 years who presented to the ED with acute limb trauma pain with a visual analgesic scale (VAS) of 5 or more on a standard 11- point (0 to 10). An informed consent is necessary.
Key exclusion criteria (10 listed)
- - Pregnancy,
- Breast-feeding,
- Altered mental status,
- Allergy to ketamine or morphine or
- Weight less than 46 kg or greater than 115 kg,
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Ketamine25mg of ketamine in 0.5 ml of serum saline in one pulverisation per nostril is received | Drug | Ketamine group |
| PlaceboAlso: normal saline solution0.5 mL of normal saline solution as a placebo in one pulverisation per nostril | Drug | placebo group |
Primary outcome
Number and percentage of patients who need rescue opiods in the two groups
Time frame: 30 minutes
the need for rescue opioids during ED stay
3 secondary outcomes
Intolerance to treatement and adverse events
Time frame: 30 minutes and at 120 minutes
Percentage of patients with VAS <30 mm at discharge
Time frame: 120 minutes
Number and percentage of patients who required non opiods analgesics
Time frame: 30 minutes
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Jul 2019.
- Individual participant dataSharing planned: No
Related trials for Trauma
Not yet recruitingPhase 4
Propofol Target-Controlled Infusion Versus Dexmedetomidine for Sedation During Chronic Subdural Hematoma Surgery Under Local Anesthesia
Chronic Subdural Hematoma
Recruiting
Functional Electrical Stimulation vs Transcutaneous Stimulation in Patients With Subacute Spinal Cord Injury
Non Traumatic Spinal Cord Injury, Sub-Acute Rehabilitation
Not yet recruiting
Examining the Effectiveness of a Brief Therapeutic Intervention for Reducing Self-Harm Among Adolescents
Self Injurious Behavior, Self Injurious Behavior Without Suicidal Intent
Recruiting
Controlled Remote Monitoring and Optimization of Oxygen Therapy in Preterm Infants
BPD - Bronchopulmonary Dysplasia, Pulmonary Hypertension
Recruiting
Virtual Reality Assisted Trauma Focused CBT
PTSD - Post Traumatic Stress Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Nouira Semir, Professor principal investigator
university Hospital of Monastir
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Ketamine in people with Trauma, run by University of Monastir at 2 sites in Tunisia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Jul 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Tunisia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number and percentage of patients who need rescue opiods in the two groups (time frame: 30 minutes). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jul 2019.